248 related articles for article (PubMed ID: 30318492)
1. Cumulative Effects of LDL Cholesterol and CRP Levels on Recurrent Stroke and TIA.
Kitagawa K; Hosomi N; Nagai Y; Kagimura T; Ohtsuki T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Nakamura M; Matsumoto M;
J Atheroscler Thromb; 2019 May; 26(5):432-441. PubMed ID: 30318492
[TBL] [Abstract][Full Text] [Related]
2. Desirable Low-Density Lipoprotein Cholesterol Levels for Preventing Stroke Recurrence: A Post Hoc Analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke).
Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
Stroke; 2018 Apr; 49(4):865-871. PubMed ID: 29511130
[TBL] [Abstract][Full Text] [Related]
3. Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
Kitagawa K; Hosomi N; Nagai Y; Kagimura T; Ohtsuki T; Origasa H; Minematsu K; Uchiyama S; Nakamura M; Matsumoto M;
J Atheroscler Thromb; 2017 Oct; 24(10):1039-1047. PubMed ID: 28302952
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein levels and outcomes after statin therapy.
Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
[TBL] [Abstract][Full Text] [Related]
5. Oxidized low-density lipoprotein (LDL) and LDL cholesterol are associated with outcomes of minor stroke and TIA.
Wang A; Dai L; Zhang N; Lin J; Chen G; Zuo Y; Li H; Wang Y; Meng X; Wang Y
Atherosclerosis; 2020 Mar; 297():74-80. PubMed ID: 32097804
[TBL] [Abstract][Full Text] [Related]
6. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
[TBL] [Abstract][Full Text] [Related]
7. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Mega JL; Morrow DA; Cannon CP; Murphy S; Cairns R; Ridker PM; Braunwald E
J Thromb Thrombolysis; 2006 Aug; 22(1):71-6. PubMed ID: 16786236
[TBL] [Abstract][Full Text] [Related]
9. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
[TBL] [Abstract][Full Text] [Related]
10. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Plehn JF; Davis BR; Sacks FM; Rouleau JL; Pfeffer MA; Bernstein V; Cuddy TE; Moyé LA; Piller LB; Rutherford J; Simpson LM; Braunwald E
Circulation; 1999 Jan; 99(2):216-23. PubMed ID: 9892586
[TBL] [Abstract][Full Text] [Related]
11. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
12. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
13. The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels.
Zhang X; Lv W; Xu J; Li J; Pan Y; Yan H; Li H; Li Z; Meng X; Wang Y
J Atheroscler Thromb; 2022 Nov; 29(11):1634-1645. PubMed ID: 35013023
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease.
Arenillas JF; Alvarez-Sabín J; Molina CA; Chacón P; Montaner J; Rovira A; Ibarra B; Quintana M
Stroke; 2003 Oct; 34(10):2463-8. PubMed ID: 14500938
[TBL] [Abstract][Full Text] [Related]
15. Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS.
Hosomi N; Kitagawa K; Nagai Y; Nakagawa Y; Aoki S; Nezu T; Kagimura T; Maruyama H; Origasa H; Minematsu K; Uchiyama S; Matsumoto M;
J Atheroscler Thromb; 2020 May; 27(5):449-460. PubMed ID: 31534062
[TBL] [Abstract][Full Text] [Related]
16. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
[TBL] [Abstract][Full Text] [Related]
17. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
Albert MA; Danielson E; Rifai N; Ridker PM;
JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein predicts further ischemic events in transient ischemic attack patients.
Purroy F; Montaner J; Molina CA; Delgado P; Arenillas JF; Chacon P; Quintana M; Alvarez-Sabin J
Acta Neurol Scand; 2007 Jan; 115(1):60-6. PubMed ID: 17156267
[TBL] [Abstract][Full Text] [Related]
19. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
20. Optimal Medical Management Reduces Risk of Disease Progression and Ischemic Events in Asymptomatic Carotid Stenosis Patients: A Long-Term Follow-Up Study.
Shah Z; Masoomi R; Thapa R; Wani M; Chen J; Dawn B; Rymer M; Gupta K
Cerebrovasc Dis; 2017; 44(3-4):150-159. PubMed ID: 28689200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
